BCRX Q4 2020 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-89.9% YoY

Gross Profit

$4M98.0% margin

Operating Income

-$52M-1304.9% margin

Net Income

-$60M-1506.3% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-34.2%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$45M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$335M

Total Liabilities

$354M

Stockholders' Equity

-$19M

Cash & Equivalents

$272M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$40M	-89.9%
Gross Profit	$4M	$37M	-89.4%
Operating Income	-$52M	-$109,000	-47978.0%
Net Income	-$60M	-$3M	-2207.1%

Revenue Segments

Collaborative and Other Research and Development

$2M57%

Royalty

$1M28%

Product

$605,00015%